Biotech Startups

GutGutGoose sequences a customer's gut microbiome, then compounds personalized probiotic formulas of 8-20 strains matched to their individual gut, diet, health history, and metabolic pathways, with a retest at 90 days to measure colonization. The consumer subscription product is sold in the US and Australia.

1 investor

GXP-Storage provides GxP-compliant regulated materials storage and lifecycle management for life sciences organizations across pre-clinical research, clinical trials, commercial manufacturing, and healthcare delivery. Its GXP-Guardian platform combines physical material records and secure e-archives into a single inspection-ready archive, serving life sciences sectors in the US and UK.

1 investor

Gyala Therapeutics develops autologous immunotherapy based on CAR-T technology targeting CD84 for cancer treatment. The company is a technology-based enterprise supported by Spanish government research and innovation programs.

1 investor

Gylden Pharma develops proprietary dermal delivery platforms for therapeutic medicines, using titanium microneedles and programmable gold nanoparticles to enable rapid, precise drug delivery through the skin. The company focuses on oncology and infectious disease applications including tumor immunotherapy and vaccine development.

1 investor

Gyre Therapeutics is a biopharmaceutical company developing small-molecule therapeutics for organ fibrosis and inflammatory diseases, with its lead program F351 in clinical evaluation for liver fibrosis in the US and China. The company also operates Cullgen Inc., a subsidiary focused on targeted protein degrader therapies for cancer and inflammatory conditions.

1 investor

Gyros Protein Technologies develops the Gyrolab platform, an immunoassay solution for bioprocess applications in the biotechnology industry. The platform enables automated protein analysis and characterization for biopharmaceutical development and manufacturing.

1 investor

Haelixa is a deep tech company, spun off from ETH Zürich, that uses DNA-based markers to verify the origin and authenticity of physical products. Its technology serves textile traceability and luxury product anti-counterfeiting needs.

1 investor

HairDAO is a decentralized research network enabling patients and researchers to collaboratively fund and develop new hair loss treatments through community voting and blockchain-based governance.

1 investor

Hale Animal Health develops novel veterinary pharmaceuticals for companion animals, focused on treatments intended to be effective and safe with fewer side effects. The company targets the pet health market.

1 investor

Halex Istar develops, manufactures, and sells ready-to-use injectable medications and large- and small-volume parenteral solutions for the hospital segment. Founded in 1959, the Brazilian pharmaceutical company serves clients nationwide and invests in R&D for incremental innovation in hospital care.

1 investor

AvantGuard develops Avantamine, an antimicrobial molecule that eliminates bacteria, viruses, and fungi on surfaces and skin without generating resistance, with an initial focus on topical treatment of the drug-resistant fungal pathogen Candida auris. The technology can be formulated as an antiseptic, disinfectant, surface coating, or plastics additive for use in healthcare settings.

1 investor

Happilabs provides Virtual Lab Manager, a tech-enabled service that handles lab procurement, supplier relations, spend tracking, and EH&S compliance for pharma and biotech R&D teams. The service allows scientists to focus on research while dedicated support manages vendor sourcing, purchase orders, invoicing, and regulatory documentation.

1 investor

Happy Bond makes shelf-stable, fresh dog food products made with human-grade ingredients and gently cooked using patent-pending technology. The company serves pet owners seeking nutritionally complete meals for dogs without artificial preservatives or synthetic additives.

1 investor

Haptena Therapeutics is a biotech company developing next-generation immunotherapies for oncogene-driven, genetically defined cancers, starting with KRAS-driven tumors. It combines targeted therapy precision with immune-based approaches to create more durable treatment options for patients with difficult-to-treat cancers.

1 investor

HapticHeart Solutions builds a device-agnostic system that converts biophysical and physiological signals from cardiac catheterization, electrophysiology, and robotic interventions into haptic feedback delivered to operators through a wearable interface and handle. It targets clinical operators performing catheter-based structural heart and cardiac electrophysiology procedures, aiming to simulate direct tactile sensing such as intracardiac pressure and catheter-tissue contact force.

1 investor

Harbinger Health develops early cancer detection technology through its Harbinger HX platform, which embeds developmental biology into biomarker discovery, assay design, and model training to detect faint biological signals of early cancer in real-world samples. The company builds tools for oncology and cancer management.

1 investor

Harbor MedTech develops collagen-based medical devices and bioimplants for surgical wound healing and tissue regeneration. The company's BriDGE technology platform produces products for orthopedic, general surgical, and chronic wound care applications.

1 investor

Harmony Pharma Group provides CMC (chemistry, manufacturing, and controls) consulting for small molecule and antibody drug conjugate development, offering technical, regulatory, and quality strategy from early bench work through clinical stages to commercialization. It also supports implementation of these plans at CDMOs on behalf of pharmaceutical clients.

1 investor

Harpe Bioherbicide Solutions develops natural, bio-based weed control products for agriculture and, through a partnership with SBM Life Science, the home and garden consumer market. The company works on next-generation bioherbicide solutions.

1 investor

Genesis Molecular uses deep learning and molecular simulation to accelerate drug discovery and development. The platform helps identify and optimize drug candidates for challenging diseases.

1 investor

University of Maryland spin-out commercializing minimally invasive image-guided surgical tool for beating heart mitral valve repair (acquired by Edwards Lifesciences in December 2017).

1 investor

Harton Therapeutics offers a GMP-ready platform for advanced 3D cell manufacturing, using a perfusion-based single-use cartridge system with automated process control to produce human cells at scale. It serves researchers, biotech and pharma teams, and manufacturing partners working on immune cell therapies, HSPCs, engineered cells, and stem-derived cells and tissues.

1 investor

Harvard Bioscience manufactures and supplies life science research tools and laboratory equipment for academic institutions and pharmaceutical companies. The company serves the research and development market with advanced instrumentation and solutions.

1 investor

Harvest Moon is developing animal-free dairy products that aim to match conventional dairy while being lactose- and cholesterol-free, lower in sugar, and higher in nutrition. Its production process uses less land, water, and energy and produces fewer GHG emissions than conventional dairy.

1 investor